approval
saveVENCLEXTA (VENETOCLAX) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026 · 162d ago
- phase 3 initiationInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)Apr 29, 2026 · 163d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalFeb 19, 2026 · 232d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 22, 2021 · 1813d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 4, 2021 · 1831d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalNov 19, 2020 · 2150d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 16, 2020 · 2184d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 16, 2020 · 2184d ago
same company · ±60 days · 5
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 16, 2022
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 16, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalApr 29, 2022
🐶 often sniffed alongside
top 7- drugVENCLEXTA82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that